ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer—Resection Cuts the Deal
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer—Resection Cuts the Deal ; volume:30 ; number:7 ; day:19 ; month:4 ; year:2023 ; pages:4429-4430 ; date:7.2023
Annals of surgical oncology ; 30, Heft 7 (19.4.2023), 4429-4430, 7.2023
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1245/s10434-023-13484-6
- URN
-
urn:nbn:de:101:1-2023091615363354444128
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Eshmuminov, Dilmurodjon
- Aminjonov, Botirjon
- Palm, Russell F.
- Lehmann, Kuno
- SpringerLink (Online service)
Other Objects (12)
Editorial: Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Conference
The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
ASO Author Reflections: Importance of Preoperative Prediction of Survival in Resectable Pancreatic Ductal Adenocarcinoma
DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer
Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study
CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer
Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
"duneR*ASO!" ASO RPO
ASo
ASO
Editorial: Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Conference
The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
ASO Author Reflections: Importance of Preoperative Prediction of Survival in Resectable Pancreatic Ductal Adenocarcinoma
DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer
Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study
CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer
Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
"duneR*ASO!" ASO RPO
ASo
ASO
Editorial: Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Conference
The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
ASO Author Reflections: Importance of Preoperative Prediction of Survival in Resectable Pancreatic Ductal Adenocarcinoma
DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer
Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study
CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer
Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
"duneR*ASO!" ASO RPO
ASo